Date: 2015-08-30
Type of information: Licensing agreement
Compound: therapeutic antibodies against an undisclosed immuno-oncology target
Company: BMS (USA - NY) QIMR Berghofer Medical Research Institute (Australia)
Therapeutic area: Cancer - Oncology
Type agreement: R&D licensing
Action mechanism: monoclonal antibody
Disease:
Details: * On August 30, 2015, BMS and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology (I-O) target. QIMR Berghofer Medical Research Institute is a world leading translational research institute focused on cancer, infectious diseases, mental health and a range of complex disorders. Bristol-Myers Squibb will be solely responsible for clinical development and commercialization of antibodies discovered through the collaboration.
Financial terms: Financial terms were not disclosed.
Latest news:
